Suppr超能文献

新兴的抗癌治疗靶点与心血管系统:是否需要引起关注?

Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?

机构信息

Cardiovascular Medicine, Vanderbilt University Medical Center, PRB 359B Pierce Ave., Nashville, TN 37232, USA.

出版信息

Circ Res. 2010 Apr 2;106(6):1022-34. doi: 10.1161/CIRCRESAHA.109.211276.

Abstract

The race for a cure to cancer continues, fueled by unprecedented discoveries of fundamental biology underlying carcinogenesis and tumorigenesis. The expansion of the target list and tools to approach them is moving the oncology community extraordinarily rapidly to clinical trials, bringing new hope for cancer patients. This effort is also propelling biological discoveries in cardiovascular research, because many of the targets being explored in cancer play fundamental roles in the heart and vasculature. The combined efforts of cardiovascular and cancer biologists, along with clinical investigators in these fields, will be needed to understand how to safely exploit these efforts. Here, we discuss a few of the many research foci in oncology where we believe such collaboration will be particularly important.

摘要

癌症治疗方法的研究仍在继续,其动力来自致癌和肿瘤发生的基础生物学的空前发现。目标清单的扩展和用于接近这些目标的工具正在使肿瘤学界迅速进入临床试验,为癌症患者带来新的希望。这一努力也推动了心血管研究中的生物学发现,因为许多在癌症中探索的靶点在心脏和血管中起着重要作用。心血管和癌症生物学家以及这些领域的临床研究人员需要共同努力,以了解如何安全地利用这些努力。在这里,我们讨论了肿瘤学中许多研究重点,我们认为在这些领域的合作将尤为重要。

相似文献

1
Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?
Circ Res. 2010 Apr 2;106(6):1022-34. doi: 10.1161/CIRCRESAHA.109.211276.
2
Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.
Ther Adv Cardiovasc Dis. 2017 Nov;11(11):297-317. doi: 10.1177/1753944717729141. Epub 2017 Sep 15.
3
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases.
Pharmacol Ther. 2020 Jun;210:107514. doi: 10.1016/j.pharmthera.2020.107514. Epub 2020 Feb 24.
4
Integrins: novel therapeutic targets for cardiovascular diseases.
Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):109-32. doi: 10.2174/187152507780363223.
5
Molecular Targets of Active Anticancer Compounds Derived from Marine Sources.
Mar Drugs. 2018 May 22;16(5):175. doi: 10.3390/md16050175.
6
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
J Natl Cancer Inst. 2010 Jan 6;102(1):14-25. doi: 10.1093/jnci/djp440. Epub 2009 Dec 10.
8
Protein Quality Control Dysfunction in Cardiovascular Complications Induced by Anti-Cancer Drugs.
Cardiovasc Drugs Ther. 2017 Feb;31(1):109-117. doi: 10.1007/s10557-016-6709-7.
9
Copper transporters and copper chaperones: roles in cardiovascular physiology and disease.
Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C186-C201. doi: 10.1152/ajpcell.00132.2018. Epub 2018 Jun 6.
10
Reactive Oxygen and Nitrogen Species-Induced Protein Modifications: Implication in Carcinogenesis and Anticancer Therapy.
Cancer Res. 2018 Nov 1;78(21):6040-6047. doi: 10.1158/0008-5472.CAN-18-0980. Epub 2018 Oct 16.

引用本文的文献

1
Targeting transcription factors in cancer drug discovery.
Explor Target Antitumor Ther. 2020;1(6):401-412. doi: 10.37349/etat.2020.00025. Epub 2020 Dec 28.
2
Induction of the ER stress response in NRVMs is linked to cardiotoxicity caused by celastrol.
Acta Biochim Biophys Sin (Shanghai). 2022 Aug 25;54(8):1180-1192. doi: 10.3724/abbs.2022104.
4
Natural and Synthetic Lactones Possessing Antitumor Activities.
Int J Mol Sci. 2021 Jan 21;22(3):1052. doi: 10.3390/ijms22031052.
5
Cyanine conjugates in cancer theranostics.
Bioact Mater. 2020 Sep 29;6(3):794-809. doi: 10.1016/j.bioactmat.2020.09.009. eCollection 2021 Mar.
7
Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes.
Int J Mol Sci. 2020 Apr 8;21(7):2581. doi: 10.3390/ijms21072581.
8
Cardiovascular and Cancer Risk: The Role of Cardio-oncology.
J Adv Pract Oncol. 2018 Mar;9(2):160-176. Epub 2018 Mar 1.

本文引用的文献

1
p53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content.
Circ Res. 2009 Sep 25;105(7):705-12, 11 p following 712. doi: 10.1161/CIRCRESAHA.109.205310. Epub 2009 Aug 20.
3
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
Cancer Chemother Pharmacol. 2010 Mar;65(4):765-73. doi: 10.1007/s00280-009-1083-9. Epub 2009 Aug 2.
5
NF-kappaB activation is required for adaptive cardiac hypertrophy.
Cardiovasc Res. 2009 Dec 1;84(3):416-24. doi: 10.1093/cvr/cvp237. Epub 2009 Jul 20.
6
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
7
Clinical development of novel proteasome inhibitors for cancer treatment.
Expert Opin Investig Drugs. 2009 Jul;18(7):957-71. doi: 10.1517/13543780903002074.
8
Ubiquitin-mediated control of oncogene and tumor suppressor gene products.
Cancer Sci. 2009 Aug;100(8):1374-81. doi: 10.1111/j.1349-7006.2009.01196.x. Epub 2009 May 19.
9
Decreased expression of microRNA-143 and -145 in human gastric cancers.
Oncology. 2009;77(1):12-21. doi: 10.1159/000218166. Epub 2009 May 12.
10
Hedgehog signalling as a target in cancer stem cells.
Clin Transl Oncol. 2009 Apr;11(4):199-207. doi: 10.1007/s12094-009-0341-y.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验